Cookie policy: This site uses cookies (small files stored on your computer) to simplify and improve your experience of this website. Cookies are small text files stored on the device you are using to access this website. For more information please take a look at our terms and conditions. Some parts of the site may not work properly if you choose not to accept cookies.

Join

Subscribe or Register

Existing user? Login

sections

Women’s health

New estimates for breast cancer risk associated with HRT

Findings from a study published in the BMJ should help identify safer treatments and provide a benchmark against which hormone replacement therapy treatments might be measured.

hrt hormone replacement therapy

Source: Shutterstock.com

The researchers analysed breast cancer risk by factors such as type of hormone replacement therapy, recent and past use, and short-term and long-term use

New estimates of the increased risks of breast cancer associated with use of different hormone replacement therapy (HRT) preparations have been published in the BMJ (28 October 2020)[1].

The team linked data from UK general practices to hospital, mortality, social deprivation and cancer registry data, and analysed breast cancer risk by HRT type; by recent and past HRT use; and by short-term and long-term HRT use.

Data for 98,611 women diagnosed with breast cancer were compared with data for 457,498 women who did not have breast cancer.

The researchers estimated that, among recent oestrogen-only HRT users, between 3 (in younger women) and 8 (in older women) extra cases of breast cancer per 10,000 women years would be expected, and in oestrogen-progestogen HRT users, there would be between 9 and 36 extra cases. For past oestrogen-progestogen users, between 2 and 8 extra cases per 10,000 women years would be expected.

The authors said that, in comparison with a meta-analysis published in The Lancet, their findings suggested generally lower increased risks for combined HRT treatments, and more pronounced declines in risk once HRT had stopped.

“Our estimates cover commonly used NHS primary care HRT treatments over 20 years,” said Yana Vinogradova, senior research fellow, University of Nottingham.

“Demonstrating the main treatment factors affecting risk levels, they should help doctors and women identify safer treatments, and provide a benchmark against which other HRT treatments might be measured.”

Citation: The Pharmaceutical Journal DOI: 10.1211/PJ.2020.20208644

Have your say

For commenting, please login or register as a user and agree to our Community Guidelines. You will be re-directed back to this page where you will have the ability to comment.

Recommended from Pharmaceutical Press

  • Print
  • Share
  • Comment
  • Save
  • Print Friendly Version of this pagePrint Get a PDF version of this webpagePDF

Newsletter Sign-up

Want to keep up with the latest news, comment and CPD articles in pharmacy and science? Subscribe to our free alerts.